Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931875 | 0.89 | PTPRC (0.59) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL9464001 | 0.86 | MAOB (0.49) | PTPRCPTPN1F2PRSS1PRSS2 | |
| SCHEMBL891492 | 0.80 | LTA4H (0.59) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL30903806 | 0.80 | ALDH1A1 (0.54) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL1259945 | 0.78 | PARP10 (0.62) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL1539440 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL5947507 | 0.78 | IDO1 (0.57) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL18460957 | 0.78 | KDM4E (0.50) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL3266332 | 0.78 | PTPRC (0.55) | SMN1; SMN2PTPRCPTPN1KDM4EF2 | |
| SCHEMBL12920460 | 0.78 | PTPRC (0.55) | SMN1; SMN2PTPRCPTPN1KDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| EP-2630127-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | Glaxo Group Limited (GB) | 2013-08-28 | — | — | EP | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| WO-2012052459-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| EP-0658541-B1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE | SHIONOGI & CO (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5510506-A | Process for producing carboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0658541-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | NLRP3, IL33, IL5 | SMN1; SMN2 4836/4885PTPRC 1937/4885PTPN1 2462/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | SMN1; SMN2 3063/4885PTPRC 1143/4885PTPN1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.